<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03544788</url>
  </required_header>
  <id_info>
    <org_study_id>RMP-002</org_study_id>
    <nct_id>NCT03544788</nct_id>
  </id_info>
  <brief_title>Evaluation of Cirvo™ Mobile Compression Device for Treatment of Venous Leg Ulcers</brief_title>
  <acronym>HEAL I</acronym>
  <official_title>HEAL I (The Treatment of Venous Leg Ulcers): Evaluation of Cirvo™ Mobile Compression Device for the Treatment of Venous Leg Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radial Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radial Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study in venous leg ulcer (VLU) patients will evaluate the use of Cirvo™ therapy for the
      treatment of VLU when applied for a minimum of two hours daily for up to 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business decision
  </why_stopped>
  <start_date type="Anticipated">June 30, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cirvo™ Therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects fully healed at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of wound epithelialized at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects fully healed at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to complete healing in fully-healed subjects</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Therapy-related adverse events will be collected throughout the 12-week study period</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Characterization of Quality of Life measured using the EQ-5D-5L</measure>
    <time_frame>Baseline, 4 weeks, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Characterization of Quality of Life measured using the WPAI:GH</measure>
    <time_frame>Baseline, 4 weeks, 12 weeks</time_frame>
    <description>WPAI:GH: Work Productivity and Activity Impairment: General Health</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterization of Disability measured using the VLU-QoL</measure>
    <time_frame>Baseline, 4 weeks, 12 weeks</time_frame>
    <description>VLU-QoL: Venous Leg Ulcer Quality of Life Instrument</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterization of Disability measured using the VCSS</measure>
    <time_frame>Baseline, 4 weeks, 12 weeks</time_frame>
    <description>VCSS: Venous Clinical Severity Score</description>
  </other_outcome>
  <other_outcome>
    <measure>Characterization of Patient Satisfaction measured using a Patient Satisfaction Survey</measure>
    <time_frame>Baseline, 4 weeks, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of compliance with Cirvo(TM) (a minimum of 2 hours of therapy daily for up to 12 weeks) - number of days of therapy use</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of compliance with Cirvo(TM) (a minimum of 2 hours of therapy daily for up to 12 weeks) - hours per day of therapy use</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Reasons for Cirvo(TM) discontinuation prior to complete healing (including, but not limited to: adverse events, self-withdrawal) will be tabulated</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>Cirvo™ Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cirvo™ Therapy</intervention_name>
    <description>The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression for the treatment of venous leg ulcers (VLU).</description>
    <arm_group_label>Cirvo™ Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients between 18 and 80 years of age

          2. Patients (CEAP 6) who have not previously experienced a period of open ulceration
             exceeding 26 weeks in the affected leg

          3. Total venous ulcer area &lt; 20cm2

          4. Duration of therapy for active venous ulcer &lt;26 weeks prior to enrollment

          5. Venous insufficiency documented by venous reflex ultrasound showing mild, moderate, or
             severe reflux in the superficial or deep venous system

        Exclusion Criteria:

          1. Acute DVT within the 3 months prior to enrollment

          2. Ulcer present for &lt;2 weeks

          3. Ulcers extending with exposed fascia, tendon, or bone within the wound margins

          4. Lateral malleolus ulcers

          5. Ulcers with perforator incompetence deep to the ulceration (within 5 cm of the wound
             border)

          6. Active infection (systemic or in the affected limb)

          7. Lower extremity gangrene

          8. Diabetes mellitus (Type I or II) requiring medication

          9. History of pulmonary vascular disease (PVD)

         10. History of pulmonary edema

         11. History of decompensated congestive heart failure (CHF)

         12. Open surgery or major trauma to the legs within the last six months

         13. History of lower limb malignancy, primary or secondary

         14. Acute symptomatic lower extremity thrombophlebitis

         15. Pregnant or breastfeeding

         16. Calf geometry on which Cirvo(TM) device does not appropriately fit

         17. Known sensitivity to any of the materials used in the Cirvo(TM) device

         18. Currently participating or plans to participate in in any other investigational
             clinical evaluation during the 12 week study period that may, in the opinion of the
             investigator, affect blood flow and/or venous leg ulcer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zuckerberg San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mobile compression device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

